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Summary
This thesis is divided in two parts. The Íirst part addresses studies of the primary
diagnosis of carcinoid tumors and the second part of this thesis deals with the
diagnosis of complications of carcinoid tumors
First ParÍ
In chapter 1 an overview is given of diagnostic strategies based on features that are
typical for carcinoid tumors. Attention is focused on biochemical markers and
radionuclide imaging procedures.
Circulating chromogranin A can be used as a tumor marker, and has a high sensitivity
and specificity for neuroendocrine tumors. However, chromogranin A can not
discriminate within the group of neuroendocrine tumors. Because serotonin is the
characteristic tumor product of carcinoid tumors, biochemical markers of serotonin
metabolism are essential for the diagnosis. Increased synthesis of serotonin is
detected by measuring the serotonin metabolite S-hydroxyindole aceticacid (5-HlAA)
in urine, or the more sensitive marker serotonin content of platelets. The
determination of other tumor products such as catecholamines and histamine, can
explain unusual symptoms in carcinoid patients.
Octreotide receptor scintigraphy (octreotide scintigraphy) visualizes pecific receptors
at the cell membrane and is recommended as a first steo in the localization of
carcinoid tumors.
The diagnostic value of  ^ various positron emission tomography (PET) tracers remains
to be determined. The 'oF-labeled deoxyglucose (FDG), which reflects increased
glucose metabolism in cancerous tissue, was studied to visualize these tumors Thrs
tracer was however not sufficiently taken up by the carcinoid tumors. Other PET
tracers involved in serotonin metabolism do however seem to be interesting.
Better knowledge about both the metabolic behavior and accurate localization of
tumor deposits wil l be helpful to optimize patient management.
Chapter 2 describes the analysis of the discriminating capacity of the indole markers
urinary 5-HlAA, urinary serotonin, and platelet serotonin in the diagnosis of carcinoid
tumors. Indole markers were measured in 688 oatients with susoected carcinoid
disease. The init ial values of indole markers from patients, in whom a carcinoid tumor
was proven during follow-up (n=98), were used for Receiver Operator Characteristic
(ROC) analysis. ROC curve analysis showed platelet serotonin to have the highest
discriminating capacity, especially in foregut carcinoids. We also used ROC analysis
to determine optimal cut-off values. For platelet serotonin a cut-off value of 5.4
nmol/1 0'platelets resulted in a sensitivity 74o/o, specificity 91%, positive predictive
value 63%, and nelative predictive value 95%. Slight increases of markers were
associated with non-carclnoid neuroendocrine tumors, non-neuroendocrine tumors.
and disturbed bowel motil i ty. lt was concluded that ROC curve analysis showed that
platelet serotonin is the most discriminating indole marker for the diagnosis of
2 1 2
I
Summary and future perspectives
carcinoid tumors. Platelet serotonin especially improved the diagnosis of carcinoids
producing smal l  amounts of  serotonin.
In chapter 3 the profi l ing of tryptophan related plasma indoles in carcinoid patients
using automated on l ine solid phase extraction with high pedormance liquid
chromatography and fluorescence detection is described. This method can be used to
determine the amount of serotonin, together with its precursors and metabolites in
one procedure. Deficiencies of tryptophan as well as excessive production of
serotonin and 5-HIAA can be determined This information can be heloful to exolain
symptoms, and customize treatment o the individual patient.
Serotonin is the principal product of carcinoid tumors. In addition, these tumors give
rise to increased excretion of urinary catecholamine metabolites Not clear is if
carcinoid tumors contain specific enzymes for catecholamine synthesis. Therefore it
was studied whether catecholamine-synthesizing enzymes (tyrosine hydroxylase,
dopamine-B-hydroxylase, phenylethanolamine-N-methyltransferase) re present in
midgut carcinoid tumors, and whether expression of these enzymes correlates with
the actual production of catecholamines. This study is described in chapter 4. We
used a three-step biotin-avidin-peroxidase m thod on paraffin-embedded tumor
specimens of 21 midgut carcinoid tumors The amount of catecholamines produced
by each tumor was estimated by measuring the urinary excretion of catecholamines
and metabolites. The results in carcinoid patients were compared to 20 patients with
pheochromocytoma (ten sporadic and ten MEN type lla related tumors) Tyrosine
hydroxylase, dopamine-B-hydroxylase and phenylethanolamine-N-methyltransferase
were demonstrated both in carcinoids and in pheochromocytomas. The percentage of
patients with positive immunohistochemistry was higher among the
pheochromocytoma patients. Among the carcinoid patients, immunoreactivity for
phenylethanolamine-N-methyltransferase w  associated with increased urinary
excretion of catecholamines or metabolites. lt was concluded that catecholamine-
synthesizing enzymes are present in carcinoid tumors. Therefore it is considered that
catecholamines can be synthesized by carcinoid tumors. using the same metabolic
pathway as pheochromocytomas.
The clinical presentation of carcinoids depends on the site of origin of the tumor, the
site of metastases and the secretory activity of the tumor These factors possibly also
determine the sensitivity of octreotide scintigraphy. In chapter 5 the role of these
factors on the imaging of carcinoid tumors with octreotide scintigraphy was evaluated.
In a retrospective, single center study we evaluated the init ial octreotide scintigraphy
of 52 carcinoid patients, with primary tumors in the foregut- (n=6), midgut region
(n=38), or with unknown primary site (n=8) Octreotide scintigraphy was compared
with all available alternative imaging procedures (conventional imaging). Tumor sites
detected with either octreotide scintigraphy or conventional imaging were used as a
standard. Sensitivity was evaluated separately for four anatomical domains: l iver-,
abdominal- (extra-hepatic), thoracic- or the peripheral domain. Serotonin secreting
activity was measured by 5-HIAA and platelet serotonin content. The sensitivity of
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octreotide scintigraphy was not related to either the primary site of the tumor or its
serotonin secreting activity. Octreotide scintigraphy and conventional imaging are
complementary for the detection of l iver metastases. Octreotide scintigraphy is more
sensitive than conventional imaging for abdominal sites, enabling the detection of a
previously unknown primary tumor. Because octreotide scintigraphy provides whole-
body imaging we recommend octreotide scintigraphy (with upper abdominal SPECT)
as a first step in the staging of carcinoid tumors. The absence of pathological lesions
in the l iver region on octreotide scintigraphy should be confirmed with upper
abdominal  u l t rasound or  CT
As carcinoid tumors can produce serotonin and catecholamines from their pr^e_cursors
tryptophan and tyrosine we studied in chapter 6 the tyrosine analogue L-3-112311lodo-
alpha-methyl-tyrosine (lMT) in the detection and in the determination of biochemical
activity of these tumors in comparison with ' '  ' ln-octreotide scintigraphy. SPECT and
planar whole-body imaging was performed 15 minutes after administration of 300
MBq IMT in 22 patients with metastatic carcinoid tumors. The number of lesions
detected was compared with 1111n-octreotide scintigraphy. Size and intensity of uptake
of all lesions were graded using a simple scoring system, yielding a total body uptake
score for both tracers These scores were compared with biochemical markers of
serotonin and catecholamine metabolism. IMT SPECT detected 43o/o f the lesions
detected bytl l ln-octreotide imag.ing. IMT SPECT performance was relatively best in
the l iver. Both IMT uptake and "ln-octreotide uptake scores correlated with markers
of serotonin metabolism No correlation with adrenaline or noradrenaline metabolites
was found. However, IMT uptake but notl11ln-octreotide uptake correlated with
dopamine metabolites excretion, as IMT uptake was higher in patients with increased
dopamine metabolite xcretion. lt was concluded that IMT uptake can be
demonstrated in  carc inoid les ions,  but  is  not  as sensi t ive ast l t ln-octreot ide.  Uptake
oÍ.t"ln-octreotide but also of IMT is related to serotonin secretory activity. IMT but not1111n-octreot ide 
uptake,  was re lated to tumor dopamine metabol ism. These f ind ings
may be oí rnterest in metabolic targeting of carcinoids.
Second ParI
Chapter 7 reviews the developments in the diagnostic and therapeutic management
of carcinoid heart disease Carcinoid patients often suffer from carcinoid heart
disease. This article reviews the histopathology, etiology, incidence, clinical
presentation, diagnosis, medical and surgrcal therapy of carcinoid heart disease.
Emphasis is put on developments in diagnostic procedures that evaluate not only
cardiac morphology but also cardiovascular function These procedures comprise
Doppler imaging, analysis of heart rate variabil ity, plasma levels of atrial natriuretic
peptide and urinary excretion of catecholamines. The use of these technrques can
lead to a better understanding of the pathophysiology of carcinoid heart disease. A
potential applic'ation of these techniques is the monitoring of drug treatment, and the
optimization of the timing of valve replacement.
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Carcinoid heart disease can lead to clinical signs of heart failure. Catecholamines
have a role in the pathophysiology of heart failure and are products of carcinoid
tumors. Both catecholamines and heart failure contribute to a derangement of
autonomic function. Therefore, we evaluated cardiovascular manifestations of
autonomic dysfunction in patients with a carcinoid syndrome as described in chapter
8. Twenty patients with a midgut carcinoid, who had a carcinoid syndrome with a
median duration of 72 months and markedly elevated urinary 5-HIAA excretion were
studied Ten patients had no symptoms of heart failure (New York Heart Association
INYHA] functional class l), 6 had class l l, and 4 class l l l  heart failure. Transthoracic
echocardiography showed righfsided valvular abnormalit ies in ' l  3 of 19 evaluable
patients. Fourteen of the 20 patients had an elevated concentration of plasma N-
terminal atrial natriuretic peptide, which correlated with NYHA class, transthoracic
echocardiography abnormalit ies, and increased urinary metanephrine xcretion.
Heart rate variabil ity parameters, in particular those associated with increased
sympathetic activity were impaired. Parameters of heart rate variabil ity were markedly
abnormal in patients with increased urinary metanephrine xcretion, but were
independent of NYHA class and transthoracic echocardiography. In these 20
carcinoid patients with substantial secreting activity oÍ the tumor, morphologic
changes of the cardiac valves were relatively mild. However, plasma N-terminal atrial
natriuretic peptide values and heart rate variabil ity profi le were markedly abnormal,
and related to enhanced urinary excretion of catecholamine and metabolites,
suggesting autonomic derangement. These abnormalit ies possibly herald the
development of more severe cardiac dysfunction and may be indicative of the need
for preventive drug treatment.
In chapter 9 troponin I, troponin T, and CKMB-mass were analyzed to detect
myocardial damage in patients with a carcinoid syndrome, who are exposed to
elevated levels of circulating serotonin. The outcomes of the troponin l, troponin T and
CKMB-mass measurements were compared between the carcinoid patients with and
without heart failure, and between patients with and without carcinoid heart disease
as determined by echocardiography. No elevated levels of troponin l, troponin T, or
CKMB-mass were found. Furthermore. no differences were observed between the
respective subgroups From these findings it was concluded that patients with a
carcinoid syndrome have no detectable signs of myocardial damage if the new and
sensitive markers are used. Even patients with prolonged exposure to high serotonin
levels, clinically observable heart failure and echocardiographic evidence of carcinoid
heart disease. show no detectable troponin I and trooonin T concentrations.
In chapter  10 the ro le of  b iochemical  markers of  bone metabol ism in the d iagnosis
and monitorjng of bone metastases in solid tumors is reviewed. In metastatic bone
disease, bone formation and resorption become uncoupled processes, leading to
abnormalit ies on plain radiography with a predominantly osteoblastic or osteolytic
appearance ln osteolytic metastases, bone resorption is enhanced without
appropriate acceleration oÍ bone formation. ln osteolytic metastases the resorption









l inks and serum collagen telopeptides are sensitive and specific markers of bone
resorption. These markers can often ldentify bone metastases before visualization by
imaging techniques. When osteolytic lesions are responding to treatment. the
physiologic oupling between bone resorption and formation is partly restored. An
increase in formation markers, bone specific isoenzyme of alkaline phosphatase,
osteocalcin and carboxyterminal propeptide of collagen type I, wil l then closely reflect
restoration of coupling.
In osteoblastic metastases, bone formation markers can accurately indicate early and
advanced bone involvement. Bone resorption markers are less sensitive for the
detection of osteoblastic lesions. The collagen telopeptides however, are resorption
markers with the abil ity to detect early bone metastases Osteoblastic lesions
responding to therapy are indicated by declining values of formation as well as
resorption markers. The precise role of the recently developed markers of bone
metabolism in early diagnosis and monitoring of bone metastases needs further
evaluation in longitudinal studies. Since the delicate derangements in bone
metabolism may be obscured in mixed patient groups, these studies should address
uniform patient groups with respect to the primary tumor type.
Treatment with somatostatin analogues and interferon u has improved control of the
carcinoid syndrome. As a result, the groMh of the tumor and the development of
metastases become more imoortant determinants for the clinical manifestations of
carcinoid tumors. At present, the optimal diagnostic approach for bone metastases in
carcinoid tumors is not known. In chapter 11 the clinical presentation of bone
metastases in oatients with carcinoid tumors is described with the aim to determine
the diagnostic value of imaging techniques and markers of bone metabolism. In a
single-center, etrospective study, 11 (8%) out of 131 patients with a carcinoid tumor
had symptomatic bone metastases All bone metastases occurred in 74 patients with
midgut carcinoids. In contrast, in 36 patients with foregut carcinoids no bone
metastases were detected. Ten of 11 oatients had oainful bone metastases. Plain
radiography had a sensitivity of 44ok, magnetic resonance imaging ' l 00%, bone
scintigraphy 90%, and octreotide scintigraphy 60% Octreotide scintigraphy and bone
scintigraphy provided complementary results in seven of nine patients. Markers of
bone metabolism could not discriminate between carcinoid patients with and those
without bone metastases. lt can be concluded that pain is the principal symptom of
bone metastases. Magnetic resonance imaging shows the highest sensitivity for bone
metastases. Both bone scintigraphy and octreotide scintigraphy have acceptable
sensitivity, and can provide complementary results.
Future perspectives
Carcinoids are malignant umors that differ from non-neuroendocrine tumors.
Diagnostic and therapeutic approaches, specific for carcinoids are based on
differences in metabolic properties. Such differences are the synthesis of biogeníc
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amines, the presence of somatostatin receptors, and a usually slow rate of
proliferation. Further elaboration of these specific approaches is needed for future
improvements in the management of carcinoid tumors.
SynÍhesis of biogenic amines
Profi l ing of the biogenic amines secreted by the tumor can be helpÍul to understand
the symptoms in an individual patient. Recently, several specific antagonists have
become available, such as antagonists for serotonin receptor subtypes, hístamine
receptor subtypes, catecholarnine receptor subtypes, and prostaglandin inhibitors. In
the future the benefits of therapy targeting on these receptor subtypes need
evaluation. Of interest is the possrbil i ty to inhrbit he endocrine activity via the p-
receptor that is present on carcinoíd cells
At present, radiolabeled or "cold" meta-iodo benzylguanidine (MIBG), is an example
of metabolic targeted treatment. Scintigraphic techniques, in partrcular PET, can
elucidate the metabolic pathways present in carcinord cells. This knowledge can be
extended towards treatment modalit ies aiming on new metabolic targets.
Presence of somatostatin receptors
Somatostatin receptor scintigraphy and somatostatin analogue treatment have
markedly improved the diagnostic and therapeutic management of carcinoid tumors.
The recognition of distinct subtypes of somatostatin receptors and subsequently, the
development of subtype-specific analogues holds promise for a further refinement of
somatostatin therapy. Radionuclide treatment, uti l izing the specific binding to
somatostatin receptors, is a fascinating new development. At present, the efficacy
and safety of this treatment modality deserves further exploration.
Proliferation rate
Carcinoids usually have a slow proliferation rate. Therefore, surgical interventions
should always be considered, also when cure is no longer possible ln the future, the
merits of extensive debulking, partial l iver resections and liver transplantation, as
pall iative or curative procedures must be determined in a collaborative ffort of
referral centers in sufficiently large studies. Carcinoid tumors are usually well
vascularized Embolization techniques exploit this characteristic. The development of
antiangiogenetic drugs may therefore also be of particular interest for the treatment of
metastatic arcinoids in the future
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